Lilly's UK Vote of Confidence
Lilly's recent decision to beef up its UK research and manufacturing facilities is a bright spot in an otherwise bleak picture of pharmaceutical investment in Europe. But rather than providing encouraging news for Europe in general, the move may simply highlight what sets the UK apart from its fellow Europeans.
You may also be interested in...
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.
Ambrx is using its technology for engineering proteins with novel amino acids--beyond the 20 that oocur in nature--to enhance the properties of proteins whose potential therapeutic uses, as well as liabilities, are known.